"10.1371_journal.pone.0029480","plos one","2011-12-28T00:00:00Z","Catherine F√©art; Catherine Helmer; Herv√© Fleury; Yannick B√©jot; Karen Ritchie; Philippe Amouyel; Susanna Schraen-Maschke; Luc Bu√©e; Jean-Charles Lambert; Luc Letenneur; Jean-Fran√ßois Dartigues","INSERM, U897, Bordeaux, France; Universit√© Bordeaux Segalen, Bordeaux, France; Department of Neurology, University Hospital of Dijon, Dijon Stroke Registry, EA4184, Faculty of Medicine of Dijon, University of Burgundy, Dijon, France; INSERM, U888, Montpellier, France; Faculty of Medicine, Imperial College London, London, United Kingdom; INSERM, UMR744, Lille, France; Institut Pasteur de Lille, University of Lille 2, Lille, France; INSERM, U837, Lille, France","Conceived and designed the experiments: CF CH LL JFD. Performed the experiments: CF CH LL JFD. Analyzed the data: CF CH LL JFD JCL KR HF YB PA SSM LB. Contributed reagents/materials/analysis tools: SSM LB JCL PA HF YB. Wrote the paper: CF CH LL JFD. Provided significant advice: HF YB KR PA SSM LB JCL.","Sanofi-Aventis has an interest in anti-Amyloid Beta antibody therapy for treating Alzheimers disease; specifically, an anti-Amyloid Beta antibody therapy is in development. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2011","12","Catherine F√©art","CF√",11,TRUE,4,4,11,4,TRUE,TRUE,FALSE,0,NA,FALSE
